Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7435955 | 0.98 | SMN1; SMN2 (0.50) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL1774552 | 0.98 | SMN1; SMN2 (0.50) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL5497458 | 0.98 | SMN1; SMN2 (0.50) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL7283594 | 0.98 | SMN1; SMN2 (0.50) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL1775038 | 0.93 | — | — | |
| SCHEMBL2906945 | 0.84 | — | — | |
| SCHEMBL1521224 | 0.81 | DPP7 (0.49) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL1521786 | 0.81 | DPP7 (0.49) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| Arcaine SCHEMBL303546 | 0.81 | MEN1 (0.62) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL28331747 | 0.80 | KDM4E (0.36) | MEN1KMT2ASMN1; SMN2HIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305198-A1 | CATIONIC LIPIDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURG (GB) | 2010-12-02 | — | — | US | claimed |
| EP-2212279-A1 | CATIONIC LIPIDS | The University Court Of The University of Edinburgh (GB) | 2010-08-04 | — | — | EP | claimed |
| WO-2009050483-A1 | CATIONIC LIPIDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2009-04-23 | — | — | WO | claimed |
| EP-0334244-A2 | Bradykinin Antagonist Peptides | THE PROCTER & GAMBLE COMPANY (US) | 1989-09-27 | — | — | EP | claimed |
| US-5401722-A | Peptide analogues | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-03-28 | — | — | US | disclosed |
| US-5378691-A | Amino acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-01-03 | — | — | US | disclosed |
| US-5328916-A | Renin inhibitors, hypotensive agents | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1994-07-12 | — | — | US | disclosed |
| US-5147857-A | Enzyme inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1992-09-15 | — | — | US | disclosed |
| EP-0501280-A2 | Renin-inhibiting peptide analogues | MERCK PATENT GmbH (DE) | 1992-09-02 | — | — | EP | disclosed |
| EP-0499080-A2 | Aminoacid derivatibes | MERCK PATENT GmbH (DE) | 1992-08-19 | — | — | EP | disclosed |
| EP-0490259-A2 | Aminoacid and peptid derivatives with renin inhibiting properties | MERCK PATENT GmbH (DE) | 1992-06-17 | — | — | EP | disclosed |
| EP-0481311-A2 | Aminoacid derivatives | MERCK PATENT GmbH (DE) | 1992-04-22 | — | — | EP | disclosed |
| EP-0456039-A2 | Renin inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1991-11-13 | — | — | EP | disclosed |
| EP-0446751-A1 | Glycolic acid derivatives | MERCK PATENT GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
| EP-0446485-A2 | Peptide analogues with renininhibiting activity | MERCK PATENT GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
| EP-0418696-A2 | Derivatives of aminoacids | MERCK PATENT GmbH (DE) | 1991-03-27 | — | — | EP | disclosed |
| EP-0339483-A2 | Renin inhbiting amino-acid derivatives | MERCK PATENT GmbH (DE) | 1989-11-02 | — | — | EP | disclosed |
| EP-0337334-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1989-10-18 | — | — | EP | disclosed |
| EP-0334244-A2 | Bradykinin Antagonist Peptides | THE PROCTER & GAMBLE COMPANY (US) | 1989-09-27 | — | — | EP | disclosed |
| EP-0333071-A2 | Polypeptides, methods for their preparation, pharmaceutical compositions comprising them and use | Eisai Co., Ltd. (JP) | 1989-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305198-A1 | CATIONIC LIPIDS | CETP, LIPA, ABHD16A | ALOX15 892/4885MEN1 1595/4885CYP1A2 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.